SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-207-0700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$55.38 million
Profitability
Miscellaneous
Employees183
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable
SI-Bone (NASDAQ:SIBN) Frequently Asked Questions
What is SI-Bone's stock symbol?
SI-Bone trades on the NASDAQ under the ticker symbol "SIBN."
How were SI-Bone's earnings last quarter?
SI-Bone Inc (NASDAQ:SIBN) announced its earnings results on Tuesday, August, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.05. The business had revenue of $16.32 million for the quarter. SI-Bone had a negative return on equity of 84.84% and a negative net margin of 46.59%. View SI-Bone's Earnings History.
When is SI-Bone's next earnings date?
What guidance has SI-Bone issued on next quarter's earnings?
SI-Bone updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $65-66.5 million, compared to the consensus revenue estimate of $65.9 million.
What price target have analysts set for SIBN?
4 brokers have issued 1-year price targets for SI-Bone's shares. Their forecasts range from $23.00 to $27.00. On average, they anticipate SI-Bone's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price. View Analyst Price Targets for SI-Bone.
What is the consensus analysts' recommendation for SI-Bone?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-Bone in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SI-Bone.
Has SI-Bone been receiving favorable news coverage?
Press coverage about SIBN stock has been trending negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SI-Bone earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for SI-Bone.
Are investors shorting SI-Bone?
SI-Bone saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 875,600 shares, an increase of 21.8% from the August 15th total of 718,900 shares. Based on an average trading volume of 170,100 shares, the short-interest ratio is currently 5.1 days. Approximately 5.6% of the shares of the company are sold short. View SI-Bone's Current Options Chain.
Who are some of SI-Bone's key competitors?
Some companies that are related to SI-Bone include Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), Silk Road Medical (SILK), AtriCure (ATRC), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Luminex (LMNX), Cryolife (CRY), Tactile Systems Technology (TCMD), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Cerus (CERS), SurModics (SRDX) and Axonics Modulation Technologies (AXNX).
What other stocks do shareholders of SI-Bone own?
Who are SI-Bone's key executives?
SI-Bone's management team includes the folowing people:
- Mr. Jeffrey W. Dunn, CEO, Pres & Chairman (Age 63)
- Dr. Mark A. Reiley M.D., Founder & Director (Age 68)
- Ms. Laura A. Francis, Chief Financial Officer (Age 52)
- Mr. Anthony J. Recupero, Chief Commercial Officer (Age 61)
- Dr. Scott A. Yerby, Chief Technology Officer (Age 51)
When did SI-Bone IPO?
(SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
How do I buy shares of SI-Bone?
Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SI-Bone's stock price today?
One share of SIBN stock can currently be purchased for approximately $16.03.
How big of a company is SI-Bone?
SI-Bone has a market capitalization of $393.70 million and generates $55.38 million in revenue each year. The company earns $-17,450,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. SI-Bone employs 183 workers across the globe.View Additional Information About SI-Bone.
What is SI-Bone's official website?
How can I contact SI-Bone?
SI-Bone's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at 408-207-0700 or via email at [email protected]
MarketBeat Community Rating for SI-Bone (NASDAQ SIBN)
MarketBeat's community ratings are surveys of what our community members think about SI-Bone and other stocks. Vote "Outperform" if you believe SIBN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIBN will underperform the S&P 500 over the long term. You may vote once every thirty days.
